EBITDA at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
The official record: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EBITDA?
- Spyre Therapeutics, Inc. (SYRE) reported EBITDA of -$57.17M in Q4 2025.
- How has Spyre Therapeutics, Inc.'s EBITDA changed year-over-year?
- Spyre Therapeutics, Inc.'s EBITDA increased by 6.7% year-over-year, from -$61.25M to -$57.17M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EBITDA?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s EBITDA has grown at a 48.4% compound annual growth rate (CAGR), from -$64.07M to -$209.56M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.